Welcome to AstraZeneca
As one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare.-
Latest features
-
Latest news collapse
-
29 October 2009
AstraZeneca PLC Third Quarter & Nine Months Results 2009
Strong business performance has been driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales. Core EPS target for the year has been increased and progress has been made on the pipeline with the approval of ONGLYZA(TM), the European submission for Brilinta and new external collaborations, tempered by the disappointing news on Zactima.
-
28 October 2009
AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC
AstraZeneca announced today that it has withdrawn the regulatory submissions for the use of ZACTIMA (vandetanib) 100mg in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) from the US FDA and the European Medicines Agency (EMEA). The applications were submitted to regulatory agencies in June 2009.
-
29 October 2009
AstraZeneca PLC Third Quarter & Nine Months Results 2009
